生物技术企业Enveric Biosciences Inc.专注于神经塑性小分子疗法的开发，针对精神与神经系统疾病。最新宣布的临床前研究显示，其领先候选药物EB-003在创伤后应激障碍(PTSD)模型中表现卓越。实验结果揭示：给药一小时后，EB-003显著降低啮齿类动物模型中的冻结行为，标志着快速恐惧消退效应。这种神经塑性药物可能增强海马体神经可塑性，同时避免幻觉风险，为PTSD治疗带来新希望。相比之下，现有FDA批准疗法如选择性血清素再摄取抑制剂(SSRIs)，仅20%至30%患者获得完全缓解，且需数周才见效。研究还将EB-003与MDMA对比，后者虽具临床益处却未获官方批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.